1. Home
  2. CYCU vs CTXR Comparison

CYCU vs CTXR Comparison

Compare CYCU & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$2.85

Market Cap

17.8M

Sector

N/A

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.85

Market Cap

19.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
CTXR
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
19.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CYCU
CTXR
Price
$2.85
$0.85
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
157.3K
1.4M
Earning Date
11-14-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,667,874.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.11
$0.63
52 Week High
$2,008.94
$5.95

Technical Indicators

Market Signals
Indicator
CYCU
CTXR
Relative Strength Index (RSI) 45.38 38.47
Support Level $2.56 $0.76
Resistance Level $3.00 $1.18
Average True Range (ATR) 0.30 0.11
MACD -0.08 -0.02
Stochastic Oscillator 27.78 38.30

Price Performance

Historical Comparison
CYCU
CTXR

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: